Loading
A phase 1/2 trial of Rituximab and Ibrutinib in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL is a phase 1/2 interventional study registered as NCT04494503 by Ascentage Pharma Group Inc., with 123 participants planned, started 2020-08-31 and due to reach its primary completion in 2024-10-20. Interventions recorded: APG-2575, Rituximab and Ibrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ascentage Pharma, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/